These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29876617)

  • 1. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.
    Incerti E; Broggi S; Fodor A; Cuzzocrea M; Samanes Gajate AM; Mapelli P; Fiorino C; Dell'Oca I; Pasetti M; Cattaneo M; Calandrino R; Gianolli L; Di Muzio N; Picchio M
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2071-2078. PubMed ID: 29876617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of pretreatment volume-based quantitative
    Kitajima K; Doi H; Kuribayashi K; Hashimoto M; Tsuchitani T; Tanooka M; Fukushima K; Nakano T; Hasegawa S; Hirota S
    Eur J Radiol; 2017 Jan; 86():176-183. PubMed ID: 28027744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes.
    Mapelli P; Broggi S; Incerti E; Alongi P; Kirienko M; Fiorino C; Dell Oca I; Fallanca F; Vanoli EG; Di Muzio NG; Gianolli L; Picchio M
    Curr Radiopharm; 2017 Aug; 10(2):102-110. PubMed ID: 28412923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma.
    Klabatsa A; Chicklore S; Barrington SF; Goh V; Lang-Lazdunski L; Cook GJ
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):276-82. PubMed ID: 24057459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive role of [
    Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A
    Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma.
    Ozmen O; Koyuncu A; Koksal D; Tatci E; Alagoz E; Demirag F; Gokcek A; Arslan N
    Nucl Med Commun; 2016 Jan; 37(1):43-9. PubMed ID: 26440572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic role of FDG PET-derived parameters in preoperative staging of endometrial cancer.
    Mapelli P; Bergamini A; Fallanca F; Rancoita PMV; Cioffi R; Incerti E; Rabaiotti E; Petrone M; Mangili G; Candiani M; Gianolli L; Picchio M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):3-9. PubMed ID: 30573387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study.
    Takahashi N; Yamamoto T; Matsushita H; Sugawara T; Kubozono M; Umezawa R; Ishikawa Y; Kozumi M; Katagiri Y; Tasaka S; Takeda K; Takeda K; Dobashi S; Jingu K
    J Radiat Res; 2016 Nov; 57(6):655-661. PubMed ID: 27422935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
    PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.
    Hall DO; Hooper CE; Searle J; Darby M; White P; Harvey JE; Braybrooke JP; Maskell NA; Masani V; Lyburn ID
    Nucl Med Commun; 2018 Feb; 39(2):161-170. PubMed ID: 29300270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K; Kuribayashi K; Minami T; Yokoyama H; Nakamura A; Hashimoto M; Kijima T; Hasegawa S; Kaida H; Yamakado K
    Oncotarget; 2024 Jun; 15():408-417. PubMed ID: 38900646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
    Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
    Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Infante JR; Cabrera J; Rayo JI; Cruz C; Serrano J; Moreno M; Martínez A; Jiménez P; Cobo A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):353-359. PubMed ID: 32605894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of 18F-FDG PET/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma.
    Ye S; Liu S; Zhou S; Xiang L; Wu X; Yang H
    Cancer Biomark; 2020; 27(2):189-194. PubMed ID: 31796665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
    Lopci E; Zucali PA; Ceresoli GL; Perrino M; Giordano L; Gianoncelli L; Lorenzi E; Gemelli M; Santoro A; Chiti A
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):667-75. PubMed ID: 25403555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic tumor volume derived from
    Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J
    Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Value of Metabolic Parameters Derived From
    Liu H; Ye Z; Yang T; Xie H; Duan T; Li M; Wu M; Song B
    Front Immunol; 2021; 12():724464. PubMed ID: 34512653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy - A prospective cohort study.
    May IJ; Nowak AK; Francis RJ; Ebert MA; Dhaliwal SS
    J Med Imaging Radiat Oncol; 2024 Feb; 68(1):57-66. PubMed ID: 37898984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
    Sharif S; Zahid I; Routledge T; Scarci M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.